135 related articles for article (PubMed ID: 35489751)
1. Chemotherapy-induced Reversion of Mutant
Sato S; Mikayama YO; Shiozawa M; Nukada S; Iguchi K; Okamoto H; Kohmura T; Kazama K; Tanaka K; Oshima T; Rino Y
Anticancer Res; 2022 May; 42(5):2625-2635. PubMed ID: 35489751
[TBL] [Abstract][Full Text] [Related]
2. NeoRAS wild-type in metastatic colorectal cancer: Myth or truth?-Case series and review of the literature.
Osumi H; Vecchione L; Keilholz U; Vollbrecht C; Alig AHS; von Einem JC; Stahler A; Striefler JK; Kurreck A; Kind A; Modest DP; Stintzing S; Jelas I
Eur J Cancer; 2021 Aug; 153():86-95. PubMed ID: 34153718
[TBL] [Abstract][Full Text] [Related]
3. Loss of RAS Mutations in Liquid Biopsies of Patients With Multi-Treated Metastatic Colorectal Cancer.
Albuquerque J; Neto da Silva D; Padrão T; Leal-Costa L; Bizarro R; Correia J; Baptista C; Machete M; Prazeres G; Margarido I; Fernandes G; Simões P; Timóteo T; Lopes F; Godinho J; Moreira-Pinto J; Rodrigues T; Faria A; Pulido C; Cirnes L; Teixeira JA; Passos Coelho JL
Oncologist; 2024 Mar; 29(3):e337-e344. PubMed ID: 38071748
[TBL] [Abstract][Full Text] [Related]
4. Anti-epidermal growth factor receptor treatment for patients with Neo
Harada K; Yuki S; Kawamoto Y; Nakamura T; Kaneko S; Ishida K; Sakamoto N; Komatsu Y
Ther Adv Med Oncol; 2023; 15():17588359231216090. PubMed ID: 38033418
[TBL] [Abstract][Full Text] [Related]
5. A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer.
Osumi H; Takashima A; Ooki A; Yoshinari Y; Wakatsuki T; Hirano H; Nakayama I; Okita N; Sawada R; Ouchi K; Fukuda K; Fukuoka S; Ogura M; Takahari D; Chin K; Shoji H; Kato K; Ishizuka N; Boku N; Yamaguchi K; Shinozaki E
Transl Oncol; 2023 Sep; 35():101718. PubMed ID: 37364334
[TBL] [Abstract][Full Text] [Related]
6. Multicentre single-arm phase II trial evaluating the safety and effiCacy of Panitumumab and iRinOtecan in NeoRAS Wild-type mEtaStatic colorectal cancer patientS (C-PROWESS trial): study protocol.
Osumi H; Ishizuka N; Takashima A; Kumekawa Y; Nakano D; Shiozawa M; Denda T; Sawada R; Ouchi K; Wakatsuki T; Narikazu B; Kato K; Yamaguchi K; Shinozaki E
BMJ Open; 2022 Sep; 12(9):e063071. PubMed ID: 36581973
[TBL] [Abstract][Full Text] [Related]
7. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials.
Arnold D; Lueza B; Douillard JY; Peeters M; Lenz HJ; Venook A; Heinemann V; Van Cutsem E; Pignon JP; Tabernero J; Cervantes A; Ciardiello F
Ann Oncol; 2017 Aug; 28(8):1713-1729. PubMed ID: 28407110
[TBL] [Abstract][Full Text] [Related]
8. CEA dynamics for predicting response after anti-EGFR monoclonal antibody treatment in metastatic colorectal cancer.
Kang S; Kim SY; Hong YS; Kim TW; Choi KE; Kim MJ; Kim JE
Sci Rep; 2023 Apr; 13(1):6735. PubMed ID: 37185297
[TBL] [Abstract][Full Text] [Related]
9. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer.
Rowland A; Dias MM; Wiese MD; Kichenadasse G; McKinnon RA; Karapetis CS; Sorich MJ
Br J Cancer; 2015 Jun; 112(12):1888-94. PubMed ID: 25989278
[TBL] [Abstract][Full Text] [Related]
10. MiR-31-3p do not predict anti-EGFR efficacy in first-line therapy of RAS wild-type metastatic right-sided colon cancer.
Boisteau E; Lespagnol A; De Tayrac M; Corre S; Perrot A; Rioux-Leclercq N; Martin-Lannerée S; Artru P; Chalabreysse P; Poureau PG; Doucet L; Coupez D; Bennouna J; Bossard C; Coriat R; Beuvon F; Bauguion L; Leclair F; Chautard R; Lecomte T; Guyetant S; Desgrippes R; Grasset D; Lhostis H; Bouhier-Leporrier K; Bibeau F; Edeline J; Galibert MD; Lièvre A
Clin Res Hepatol Gastroenterol; 2022 May; 46(5):101888. PubMed ID: 35189426
[TBL] [Abstract][Full Text] [Related]
11. FOLFOX plus anti-epidermal growth factor receptor (EGFR) monoclonal antibody (mAb) is an effective first-line treatment for patients with RAS-wild left-sided metastatic colorectal cancer: A meta-analysis.
Chen D; Li L; Zhang X; Gao G; Shen L; Hu J; Yang M; Liu B; Qian X
Medicine (Baltimore); 2018 Mar; 97(10):e0097. PubMed ID: 29517682
[TBL] [Abstract][Full Text] [Related]
12. Survival Outcomes in Patients With RAS Wild Type Metastatic Colorectal Cancer Classified According to Köhne Prognostic Category and BRAF Mutation Status.
Siena S; Rivera F; Taieb J; Peeters M; Prenen H; Koukakis R; Demonty G; Köhne CH
Clin Colorectal Cancer; 2018 Mar; 17(1):50-57.e8. PubMed ID: 29096990
[TBL] [Abstract][Full Text] [Related]
13. Role of Anti-Epidermal Growth Factor Receptor Therapy Compared with Anti-Vascular Endothelial Growth Factor Therapy for Metastatic Colorectal Cancer: an Update Meta-Analysis of Randomized Clinical Trials.
Wang JX; Wu HL; Zhu M; Zhou R
Pathol Oncol Res; 2020 Jan; 26(1):159-166. PubMed ID: 29383654
[TBL] [Abstract][Full Text] [Related]
14. Ultra-selection of metastatic colorectal cancer patients using next-generation sequencing to improve clinical efficacy of anti-EGFR therapy.
Vidal J; Bellosillo B; Santos Vivas C; García-Alfonso P; Carrato A; Cano MT; García-Carbonero R; Élez E; Losa F; Massutí B; Valladares-Ayerbes M; Viéitez JM; Manzano JL; Azuara D; Gallego J; Pairet S; Capellá G; Salazar R; Tabernero J; Aranda E; Montagut C
Ann Oncol; 2019 Mar; 30(3):439-446. PubMed ID: 30689692
[TBL] [Abstract][Full Text] [Related]
15. Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).
Palmieri LJ; Mineur L; Tougeron D; Rousseau B; Granger V; Gornet JM; Smith D; Lievre A; Galais MP; Doat S; Pernot S; Bignon-Bretagne AL; Metges JP; Baba-Hamed N; Michel P; Obled S; Vitellius C; Bouche O; Saban-Roche L; Buecher B; des Guetz G; Locher C; Trouilloud I; Goujon G; Dior M; Manfredi S; Soularue E; Phelip JM; Henriques J; Vernery D; Coriat R
Oncologist; 2020 Feb; 25(2):e266-e275. PubMed ID: 32043796
[TBL] [Abstract][Full Text] [Related]
16. Recommendations from the EGAPP Working Group: can testing of tumor tissue for mutations in EGFR pathway downstream effector genes in patients with metastatic colorectal cancer improve health outcomes by guiding decisions regarding anti-EGFR therapy?
Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group
Genet Med; 2013 Jul; 15(7):517-27. PubMed ID: 23429431
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis comparing the efficacy of anti-EGFR monoclonal antibody therapy between KRAS G13D and other KRAS mutant metastatic colorectal cancer tumours.
Rowland A; Dias MM; Wiese MD; Kichenadasse G; McKinnon RA; Karapetis CS; Sorich MJ
Eur J Cancer; 2016 Mar; 55():122-30. PubMed ID: 26812186
[TBL] [Abstract][Full Text] [Related]
18. Prospective Biomarker Study in Advanced RAS Wild-Type Colorectal Cancer: POSIBA Trial (GEMCAD 10-02).
García-Albéniz X; Alonso V; Escudero P; Méndez M; Gallego J; Rodríguez JR; Salud A; Fernández-Plana J; Manzano H; Zanui M; Falcó E; Feliu J; Gil M; Fernández-Martos C; Bohn U; Alonso C; Calderero V; Rojo F; Cuatrecasas M; Maurel J
Oncologist; 2019 Nov; 24(11):e1115-e1122. PubMed ID: 31235483
[TBL] [Abstract][Full Text] [Related]
19. Chemotherapy With or Without Anti-EGFR Agents in Left- and Right-Sided Metastatic Colorectal Cancer: An Updated Meta-Analysis.
Wang ZX; Wu HX; He MM; Wang YN; Luo HY; Ding PR; Xie D; Chen G; Li YH; Wang F; Xu RH
J Natl Compr Canc Netw; 2019 Jul; 17(7):805-811. PubMed ID: 31319395
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of anti-EGFR monoclonal antibodies combined with different chemotherapy regimens in patients with RAS wild-type metastatic colorectal cancer: A meta-analysis.
Sun H; Li Y; Su Y; Wu X; Zhou X; Han J; Li J
J Evid Based Med; 2019 Nov; 12(4):300-312. PubMed ID: 31596544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
